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Purpose: To test whether serum transforming growth factor-beta 1 (TGF-b1) predicts incident and
progressive hip or knee radiographic OA (rOA).
Methods: Serum TGF-b1 was measured for 330 participants aged 45 years and older in the Johnston
County Osteoarthritis Project, with paired longitudinal ﬁlms available for 618 hips and 658 knees.
Incident and progressive rOA were deﬁned using KellgreneLawrence (KeL) grade as well as osteophyte
(OST) and joint space narrowing (JSN) scores. Natural logarithm transformation was used to produce
near-normal distributions for continuous TGF-b1 (lnTGF-b1). Separate multivariable Weibull regression
models were used to provide hazard ratios (HRs) for a 1-unit increase lnTGF-b1 with each rOA outcome,
accounting for variable follow-up times and clustering by individual, adjusted for age, race, gender, and
body mass index (BMI). Interaction terms were considered statistically signiﬁcant at P< 0.10.
Results: The mean (SD) age of the sample was 61.9 9.7 years, the mean BMI was 30.3 6.9 kg/m2, with
60.6% women and 42.4% AA. The mean (SD) TGF-b1 was 17.8 6.1 ng/ml; follow-up time was 6.1 1.3
years. There were no signiﬁcant interactions by race or gender. HRs showed no signiﬁcant relationship
between lnTGF-b1 and incident or progressive rOA, OST, or JSN, at the knee or the hip.
Conclusions: Levels of TGF-b1 do not predict incident or progressive rOA, OST, or JSN at the hip or knee in
this longitudinal, population-based study, making it unlikely that TGF-b1 will be a robust biomarker for
rOA in future studies.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
There are as yet no proven effective disease-modifying agents
for osteoarthritis (OA), one of the most common causes of disability
in the US1. One of the main reasons for the lack of effective inter-
ventions is the lack of an accepted “gold standard” measure ofose of the authors and do not
ters for Disease Control and
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s Research Society International. Pincident and progressive OA. Semiquantitative joint space nar-
rowing (JSN) and global measures such as the KellgreneLawrence
(KeL) grade from conventional radiographs are widely used to
determine OA progression at the knee or the hip, but can be
insensitive to change over time2,3. Due to the lack of highly sensi-
tive radiographic outcome measures, studies, especially clinical
trials, using these outcomes must have follow-up times on the
order of years, making such studies prohibitively time-consuming
and expensive. Magnetic resonance imaging (MRI) may in the
future replace conventional radiographs as the modality of choice
for imaging in knee OA4,5, but is currently plagued by lack of
availability, lack of accepted and widely validated scoring systems,
long examination and interpretation times, and cost, and little has
been published on MRI in hip OA6. There is a need for better
markers of disease incidence and progression in OA. As such,ublished by Elsevier Ltd. All rights reserved.
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readily available, requiring only blood or urine collection, repeat-
able, and relatively inexpensive.
Transforming growth factor-beta 1 (TGF-b1) is a multifunctional
growth factor with an important role in cartilage matrix metabo-
lism, making it an attractive potential biomarker of OA. A few
studies examining serum TGF-b1 as a potential biomarker of OA
have shown varying results7e10. The TGF-b family consists of three
closely related isoforms, TGF-b1, -b2, and -b3, with TGF-b1 being
the most abundant and most often studied in relation to bone and
OA11. Compared to controls, patients with OA have elevated TGF-b1
in synovium12, elevated TGF-b1 expression in mesenchymal stem
cells13, and elevated expression of all three TGF-b isoforms in
cartilage14. Exogenous administration of TGF-b1 into murine knee
joints leads to increased proteoglycan content in superﬁcial regions
of articular cartilage, focal proteoglycan loss in deeper areas, and
chondrophyte/osteophyte formation similar to that seen in human
OA15,16. Inhibition of endogenous TGF-b (all isoforms), while
dramatically decreasing osteophyte (OST) size, also signiﬁcantly
increases proteoglycan loss17. In rabbits, levels of TGF-b1, shortly
after meniscectomy, reﬂect longer-term bone and cartilage
changes18, suggesting that this marker has the potential to predict
OA incidence and progression.
We ﬁrst became interested in TGF-b1 as a biomarker of radio-
graphic OA (rOA) given the role of TGF-b1 in OST formation, higher
levels of TGF-b1 among African Americans compared to Cauca-
sians8,19, and our observation of higher OST burden among African
Americans compared to Caucasians20,21. We recently reported the
results of a cross-sectional analysis of TGF-b1 and rOA, which did
not demonstrate an associationwith the presence or severity of hip
or knee OA, although there was a borderline signiﬁcant association
between prevalent OST and OST severity that was seen only in
African Americans and not in Caucasians8. Considering the anabolic
role of TGF-b in OST formation, which is often an early ﬁnding in
OA, we hypothesized that TGF-b may be an important biomarker
for incident OA. The current analysis was designed to assess the
relationship between baseline TGF-b1 levels and the incidence and
progression of rOA, separately for hips and knees, overall and
stratiﬁed by race, using both KellgreneLawrence grade and indi-
vidual radiographic features (OST and JSN).
Patients and methods
Baseline data from 330 participants aged 45 years and older in
the Johnston County Osteoarthritis Project were used in the
analysis. These patients were seen for a baseline visit (1991e1997)
and a follow-up visit (1999e2003), approximately 5 years later.
Participants for baseline biomarker assessment were selected using
a simple random sampling procedure to represent approximately
equal proportions of African Americans, Caucasians, women, men,
and those with and without knee rOA, with a representative range
of ages; for the current analysis, we required complete radiographic
data at baseline and a follow-up visit, resulting in the inclusion of
330 individuals. Subject recruitment and overall project design
procedures have been described for the parent study22. Demo-
graphic and clinical information was obtained by interview,
including self-reported race. Participants underwent a clinical
evaluation which included measurement of height (m) without
shoes and weight (kg) measured with a balance beam scale, fol-
lowed by calculation of body mass index (BMI, in kg/m2). All
included participants underwent standardized bilateral weight-
bearing anteroposterior radiography of the knees in extension
using foot mat positioning with a horizontal X-ray beam centered
at the level of the superior patellae. Standardized supine ante-
roposterior pelvic radiographs were taken in 10e15 of internalrotation with the X-ray beam centered approximately 2.5 cm
superior to the pubic symphysis. Women under 50 years of age did
not undergo pelvic radiography andwere excluded from analyses of
hip rOA. Radiographs were read paired without knowledge of
participant clinical status or chronological order of the ﬁlms by
a single radiologist (JBR) using the KeL radiographic atlas23; inter-
and intra-rater reliability for this reader are high (k¼ 0.86 and 0.89,
respectively)24.
Incident rOA at the hip or knee was deﬁned in two ways:
“Incident rOA 1” (development of KeL grade 1 from a baseline
KeL grade¼ 0), and “Incident rOA 2” (development of KeL grade
2 from a baseline KeL grade<2). Progression of rOAwas similarly
deﬁned: “Progressive rOA 1”was an increase by1 KeL grade from
a baseline KeL grade 1, while “Progressive rOA 2”was an increase
of 1 KeL grade from a baseline KeL grade 2. Additionally, to
estimate effects on OA in multiple joints (hips or knees), the
development of KL 2 in an additional joint, in individuals with
a baseline KeL grade 2 in at least one joint, was considered as
a separate outcome. Incident OST and JSN were deﬁned as joints
with grade¼ 0 at baseline and 1 at follow-up, based on the
Burnett atlas25; progressionwas deﬁned as an increase of 1 grade
from a baseline grade 1.
After collection at the baseline clinic visit, blood and sera were
separated and stored on ice. Sera were frozen within 8 h of
collection at 20C, then transferred for long-term storage to
a 86C environment. The samples were analyzed at Duke
University Medical Center (by TS), where TGF-b1 was measured
using a sandwich ELISA kit from Biosource International (Camarillo,
CA). This method includes an extraction step to release TGF-b1 from
latent complexes, thus measuring total serum concentrations.
Manufacturer reported precision for this kit was 5.5e6.2% intra-
assay CV, and 6.6e7.9% inter-assay CV. Actual inter-assay CV for
the assays performed for this study was <6.2%.
The natural logarithm transformationwas used to produce near-
normal distributions for TGF-b1 (lnTGF-b1) in analyses. Descriptive
statistics were calculated for race, gender, age, BMI, and lnTGF-b1.
Separate multivariable Weibull regression models were used to
provide hazard ratios (HRs) for a 1-unit increase lnTGF-b1 with
each rOA outcome, accounting for variable follow-up times and
clustering of joints by individual. Cox proportional hazard models,
estimating the time of each OA outcome as the midpoint of the
follow-up period, were run for comparison with Weibull models
and showed similar results; the results of the Weibull models are
presented. Models were adjusted for race and gender as categorical
variables, and for age and BMI as continuous variables. Interaction
terms were considered statistically signiﬁcant at P< 0.10. Due to
prior results suggesting stronger associations among African
Americans, stratiﬁcation by race was also planned, regardless of
interaction results, as an exploratory analysis. Analyses were per-
formed using SAS version 9.1 (Cary, NC) with Stata 10 (College
Station, TX) for the Weibull models.
Results
Three hundred and thirty individuals had TGF-b1 measure-
ments; of these, 329 had paired knee ﬁlms and 309 had paired hip
ﬁlms available for longitudinal analysis. The mean (SD) age of the
overall sample was 61.9 9.7 years, with a mean BMI of
30.3 6.9 kg/m2 (Table I). Of the participants overall, 61% were
women and 42% were African American. Because women less than
50 years of age did not undergo hip radiography andwere therefore
excluded from hip-based analyses, there were fewer women with
paired hip ﬁlms, and that group was slightly older than the overall
sample (Table I). The mean (SD) serum TGF-b1 level was
17.8 6.1 ng/ml (range 6.1e40.9 ng/ml). Follow-up time ranged
Table I







Age (years) 61.9 (9.7) 61.9 (9.7) 62.3 (9.3)
BMI (kg/m2) 30.3 (6.9) 30.3 (6.9) 30.2 (6.7)
Female (%) 60.6 60.8 59.2
African American (%) 42.4 42.6 40.8
* Given as mean (SD) or percentage.
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no statistically signiﬁcant interactions by race or gender. Differ-
ences between the values of HR point estimates and 95% conﬁdence
intervals (CIs) were minimal before and after adjustment; the
results adjusted for age, gender, race, and BMI are presented.
Incident rOA
As shown in Table II, there were no signiﬁcant associations
between lnTGF-b1 and incident rOA at the hip or the knee. All of the
CIs include 1.0, and therefore show no signiﬁcant alteration in HRs
for rOA associated with lnTGF-b1 levels. Similarly, baseline lnTGF-
b1 levels did not predict incident JSN at the hip or at the knee, and
although there was a 40% increase in the HR for incident OST at
both the hip and knee, this did not reach statistical signiﬁcance
(Table II). The HRs were also not signiﬁcant after stratiﬁcation by
race (Incident OST at the knee for African Americans n¼ 33, HR
0.50, 95% CI 0.12e2.08; for Caucasians n¼ 61, HR 2.06, 95% CI
0.66e6.48).
Progressive rOA
Table III shows the adjusted HRs for progressive rOA at the hip or
knee, again without signiﬁcant association between HRs for
progressive rOA and lnTGF-b1 levels. There were small numbers for
progressive rOA at the hip, especially for progression from a base-
line KeL grade 2 (progressive rOA 2), and for progressive JSN. The
risk of progressive knee rOA by either KeL deﬁnition was 40e50%
higher in association with higher lnTGF-b1 levels, and there was an
apparent 45% reduction in risk for progressive OST at the hip and
the knee, but these relationships did not reach statistical signiﬁ-
cance (Table III). Stratiﬁcation by race did not identify signiﬁcant
associations, but there was again a suggestion of reduction in HR
among African Americans for progressive OST at the knee (n¼ 62;
HR 0.39, 95% CI 0.15e1.03) compared to Caucasians (n¼ 14, HR 2.14,
95% CI 0.36e12.7). The HR for progressive JSN at the knee was not
signiﬁcantly increased for either African Americans (n¼ 59, HR
1.64, 95% CI 0.66e4.09) or Caucasians (n¼ 25, HR 1.10, 95% CI
0.26e4.70).
We also considered individuals (n¼ 57) who had a KeL grade of
2 at least one joint at baseline, and then developed KeL grade 2
at an additional hip or knee that was not involved at baseline. TheTable II
Adjusted HRs for serum TGF-b1 and incident rOA
Incident rOA outcome n (hips with outcome) A
r
Incident rOA 1 from baseline KeL< 1 to KeL 1 54 1
Incident rOA 2 from baseline KeL< 2 to KeL 2 45 0
Incident OST from grade 0 to grade 1 49 1
Incident JSN from grade 0 to grade 1 29 0
* Adjusted for age, gender, race, and BMI.
y HR for a 1-unit increase in serum TGF-b1.adjusted HR for this outcome was 1.08 (95% CI 0.45e2.61), again
indicating no signiﬁcant association between lnTGF-b1 levels and
development or progression of OA.
Discussion
In this analysis, levels of TGF-b1 did not predict development of
incident rOA, OST, or JSN in the hip or knee. The small increase in
progressive knee rOA risk with higher TGF-b1 was not statistically
signiﬁcant, despite a large proportion of the sample having these
outcomes. There was no association between TGF-b1 levels and
progression of rOA in additional joint sites (across both knees and
both hips). The small, non-signiﬁcant alterations in risk identiﬁed
in the current study, despite a large overall sample size and fairly
large proportion with most of the outcomes of interest, demon-
strate that serum TGF-b1 is not likely to be a robust biomarker of
rOA. This is in agreement with our ﬁndings in a cross-sectional
study looking at prevalence and severity of rOA, in which no
signiﬁcant associations were seen with levels of serum TGF-b18.
Despite our prior ﬁndings of greater OST burden in African
Americans20,21 and the trend toward higher TGF-b1 with more
severe OST grades8, we did not see any interactions by race in the
current analysis, and stratiﬁed analysis did not reveal signiﬁcant
differences. We had limited power to detect interactions and
differences by race due to a small number of outcomes by race in
stratiﬁed analyses. There was a suggestion of reduction in risk of
both incident and progressive OST at the knee with higher baseline
serum TGF-b1 levels among African Americans. However, the
differences were not statistically signiﬁcant, and there were small
numbers for some of the outcomes following stratiﬁcation, so these
ﬁndings must be considered very cautiously. One could speculate
that there may be higher levels of synovial TGF-b1 acting locally
leading to these ﬁndings, but we did not have synovial ﬂuid levels
to evaluate this.
Prior studies of TGF-b1 in OA have failed to show consistent
results. Otterness and colleagues assessed a panel of biomarkers in
a case control study with 12 month follow-up and biomarker
measurement at multiple time points. In agreement with our cross-
sectional study of the current cohort8, they found that levels of
TGF-b1 did not discriminate between individuals with OA (by
American College of Rheumatology (ACR) criteria) and controls7.
They did identify a borderline association between baseline TGF-b1
levels and change in clinical status (as determined by change in
symptoms and patient/physician assessments) at 12 months,
primarily because of an association between patient global assess-
ment and baseline TGF-b110. Another group, using radiographic data
in addition to clinical criteria, showed a small, negative correlation
(r¼0.19, P value 0.01) between baseline TGF-b1 level and KeL
grade at the knee, but in contrast to the Otterness study, no associ-
ations were seen with clinical outcomes at baseline or 18 month
follow-up9. These studies, in combinationwith thenegative results of
the current study, suggest that serumTGF-b1 is unlikely tobea useful
biomarker for future study in OA.djusted* HRy for hip
OA (95% CI)
n (knees with outcome) Adjusted* HRy for knee
rOA (95% CI)
.05 (0.31e3.51) 94 1.04 (0.41e2.65)
.61 (0.25e1.47) 103 1.10 (0.46e2.63)
.41 (0.38e5.25) 94 1.41 (0.56e3.56)
.65 (0.20e2.09) 99 1.39 (0.50e3.88)
Table III
Adjusted HRs for progressive rOA
Progressive rOA outcome n (hips with outcome) Adjusted* HRy for
hip rOA (95% CI)
n (knees with outcome) Adjusted* HRy for
knee rOA (95% CI)
Progressive rOA 1 increasing 1 grade from baseline KeL 1 47 1.02 (0.46e2.28) 160 1.51 (0.82e2.79)
Progressive rOA 2 increasing 1 grade from baseline KeL 2 10 2.74 (0.31e24.30) 86 1.36 (0.63e2.91)
Progressive OST increasing 1 grade from baseline OST 1 19 0.55 (0.12e2.59) 76 0.55 (0.24e1.26)
Progressive JSN increasing 1 grade from baseline JSN 1 7 4.14 (0.62e27.7) 84 1.40 (0.64e3.03)
* Adjusted for age, gender, race, and BMI.
y HR for a 1-unit increase in serum TGF-b1.
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and the small number of hips demonstrating progression, espe-
cially for those progressing beyond KeL grade 2 and with
progressive JSN. We had only a single measurement of TGF-b1 at
baseline rather than repeatedmeasures at multiple time points. We
had radiographic data only for the hips and knees, and therefore
cannot account for OA at other joint sites. As in most large
epidemiologic studies26, the hip radiographs in this study are
non-weightbearing, and there remains controversy in the literature
regarding the beneﬁts of weight-bearing vs non-weight-bearing
standardized hip radiographs27,28. Also, and primarily for logistic
reasons, because of the size and complexity of the parent study, it
was not possible to control for diurnal variation, exercise levels,
postural changes, or dietary intake that may alter serum TGF-b1
levels29. A study of diurnal variation in OA biomarkers by Kong and
colleagues demonstrated a correlation between TGF-b1 levels and
summed KeL grade for both knees, but only at the end of the day
(r2¼ 0.35, P¼ 0.006), with no correlation between KeL grade and
morning TGF-b1 levels, before or after food intake or activity30. The
local action of TGF-b1 in the joint, as suggested by animal studies of
exogenous supplementation and endogenous inhibition of TGF-
b115,17, suggest the potential usefulness of this marker as measured
in synovial ﬂuid. However, as the need for biomarkers is primarily
to facilitate large, longitudinal studies and clinical trials of thera-
peutics, evening collections and invasive procedures such as
arthrocentesis, even if stronger associations were seen, would
make this marker impractical.
The strengths of our study are the inclusion of African American
and Caucasian men and women and the collection of longitudinal
radiographic data at two large joint sites over a mean of 6 years.
This is the largest longitudinal study to date of TGF-b1 as
a biomarker of rOA. Although we have observed higher levels of
TGF-b1 among African American individuals, there is no race
interaction for the relationship of rOA and TGF-b1, indicating no
signiﬁcant difference by race in the effect of this growth factor.
Despite the large size of our sample and the use of a joint-based
analysis to maximize sample size for this longitudinal analysis,
we did not identify signiﬁcant associations between serum TGF-b1
levels and incident or progressive rOA at the hip or knee. This
ﬁnding, in combinationwith the lack of association identiﬁed in our
cross-sectional analysis, indicates that serum TGF-b1 is unlikely to
be a robust biomarker of OA for future studies.
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